DBV Technologies | DBVT - Net Income

Stock Price
23.37
Daily Change
0.87 3.87%
Monthly
37.55%
Yearly
410.26%
Q1 Forecast
21.05

DBV Technologies reported $-33.16M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amarin USD -7.74M 6.4M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Halozyme Therapeutics USD 175.22M 10.06M Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
Insmed USD -370.02M 48.34M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
United Therapeutics USD 338.7M 29.2M Sep/2025